Stockhub

Mendus AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 04:5104:51, 16 August 2022‎ Paris talk contribs‎ 987 bytes +987‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the tre..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Mendus_AB’